Aesica Doubles Development Capacity
Aesica adds development capability at Queenborough with the opening of a new purpose-built facility.
Aesica Pharmaceuticals, a pharmaceutical contract development and manufacturing organization, announced on April 5, 2016 it has doubled its development capacity with the addition of the ability to manufacture multiple drug products up to Phase III clinical trials at its Queenborough facility.
Aesica is now able to develop and manufacture a customer product from early formulation development through clinical manufacture and commercialization.
According to a press announcement, the company’s highly potent and controlled drugs service offering has been expanded at Queenborough as a result of the new center. The company now offers full formulation and development capabilities in these specialist fields. The site handles highly potent drugs for any active up to SafeBridge Category 3, together with controlled drugs, with licenses for both schedules 2 to 4.
Source: Aesica
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
